Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mederi CE marks second-gen Secca and Stretta systems

This article was originally published in Clinica

Executive Summary

Mederi Therapeutics has CE marked its second-generation Stretta and Secca systems for sale in Europe. Stretta, a therapy for gastroesophageal reflux disease, involves insertion of the Stretta catheter through the patient’s mouth and into the valve between the stomach and oesophagus. Radiofrequency energy is delivered to the lower oesophageal sphincter and gastric cardia to create small thermal lesions. When these lesions heal, the tissue contracts, narrowing the opening to the oesophagus and preventing reflux. The Secca system is designed to treat bowel control disorder, or BCD. It uses a similar technique to contract the anal sphincter. These latest versions of the systems have an improved interface, are easier to use, and are smaller, lighter, and highly portable, the Greenwich, Connecticut firm says.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel